Protocol Ledger

NCT07223814 · Phase III · RECRUITING

Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

Interventional Phase III clinical trial protocol NCT07223814 sponsored by Stichting Hemato-Oncologie voor Volwassenen Nederland in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-01 Enrollment: 875 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07223814
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)875 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07223814
Protocol FieldVerified Registry Value
NCT IdentifierNCT07223814
Consolidated Lead SponsorStichting Hemato-Oncologie voor Volwassenen Nederland
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment875 participants (ESTIMATED)
Registered Start Date2026-03-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07223814
Hospital Research SiteLocationSite Profile
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CAOpen Hospital Dossier ->
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI